Galectin Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $38,072,000.
Profit Margin
| 2014 | 0 | -15.78M | |
|---|---|---|---|
| 2015 | 0 | -20.02M | |
| 2016 | 0 | -21.43M | |
| 2017 | 0 | -16.23M | |
| 2018 | 0 | -13.9M | |
| 2019 | 0 | -13.38M | |
| 2020 | 0 | -23.51M | |
| 2021 | 0 | -30.97M | |
| 2022 | 0 | -39.2M | |
| 2023 | 0 | -41.06M |
GALT Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 33K | 32K | 41K | 36K | 35K | 0 | 1K | 7K | 7K | 0 |
Gross profit | -33K | -32K | -41K | -36K | -35K | 0 | -1K | -7K | -7K | 0 |
Operating exp. | ||||||||||
Research and development | 32.13M | 31.73M | 23.81M | 17.97M | 7.46M | 6.47M | 11.72M | 15.32M | 13.11M | 8.42M |
Selling and marketing | 44K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 38.07M | 38.35M | 30.17M | 23.44M | 13.43M | 13.60M | 16.24M | 21.48M | 20.07M | 15.43M |
Operating income | -38.07M | -38.35M | -30.17M | -23.44M | -13.43M | -13.60M | -16.24M | -21.48M | -20.07M | -15.43M |
Other income (expenses), net | -2.99M | -424K | -348K | -21K | 144K | -298K | 12K | 45K | 52K | -358K |
Income before tax | -41.06M | -38.77M | -30.52M | -23.46M | -13.29M | -13.9M | -16.23M | -21.43M | -20.02M | -15.78M |
Income tax expense | 0 | 424K | 448K | 51K | 87K | 0 | 24K | 0 | 0 | -52K |
Net income | -41.06M | -39.2M | -30.97M | -23.51M | -13.38M | -13.9M | -16.23M | -21.43M | -20.02M | -15.78M |
Earnings per share | ||||||||||
Basic EPS | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 |
Diluted EPS | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |